HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. “The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology,” reads the article. “HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. In doing so, HeartBeam is addressing one of modern medicine’s most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, and ischemia is a future goal.”
At a glance
- Company
- HeartBeam Inc.
- Ticker
- NASDAQ: BEAT
- Announcement
- Award
Key figures
- Worldwide 12-lead ECG innovation ranking
- second
- Firms analyzed
- 243
- U.S. patents
- 13
- International-issued patents
- 4
Products and programs
To view the full article, visit https://ibn.fm/3ADRP
About HeartBeam Inc.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
HeartBeam says it ranked second worldwide for 12-lead ECG innovation among 243 firms assessed in PatentVest’s “Total Cardiac Intelligence” report, behind GE Healthcare. The company was also featured for recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics. HeartBeam describes its synthesis-ECG system as capturing electrical signals in three dimensions and combining them into a 12-lead ECG. The release says the technology is intended for portable devices that can be used outside traditional medical facilities. HeartBeam states that its system is currently cleared for arrhythmia, while ischemia remains a future goal. The company also reports holding 13 U.S. patents and 4 international-issued patents related to its technology.
Key takeaways
- HeartBeam reports a second-place worldwide ranking in 12-lead ECG innovation among 243 firms assessed.
- PatentVest’s report recognized the company in portable cardiac diagnostics, according to the release.
- The company says its system synthesizes three-dimensional cardiac electrical signals into a 12-lead ECG.
- HeartBeam says its technology is cleared for arrhythmia; ischemia is a future goal.
SEC filings
Earlier from HeartBeam Inc.
- HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
- HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
- HeartBeam (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates
